Direct Oral Anticoagulant for the Prevention of Thrombosis in Ambulatory Patients with Cancer: A Systematic Review and Meta-Analysis.

CONCLUSIONS: Low-dose DOAC reduces the rate of overall VTE in higher-risk cancer patients starting systemic chemotherapy. It may reduce the rate of symptomatic VTE but increase the likelihood of bleeding. This article is protected by copyright. All rights reserved. PMID: 31420937 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31420937?dopt=Abstract

Source: Thrombosis and Haemostasis - August 16, 2019 Category: Hematology Authors: Li A, Kuderer NM, Garcia DA, Khorana AA, Wells PS, Carrier M, Lyman GH Tags: J Thromb Haemost Source Type: research